TC-510

N/A

Report date: 2024/07/16 15:40:50

Base Information

Drug NameTC-510
Drug Alias NameTC-510
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD28
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTcr2 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTcr2 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A